DTU Logo
Overview | 4-T | ACE | ADOPT | AFORRD | DREAM | EDIT | EXSCEL | FHS | GLINT | ISAT | LDS | NAVIGATOR | TECOS | UKPDS

Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research

NAVIGATOR logo


Publications (3 of 24)


Search Publications :

2010

Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials
Henry Krum, John J.V. McMurray, Edward Horton, Teresa Gerlock, Bjoern Holzhauer, Lineke Zuurman, Steven M. Haffner, M. Angelyn Bethel, Rury R. Holman, Robert M. Califf
Cardiovascular Therapeutics 2010;28(2):124-132. Published:29-Apr-2010. PMID:20184589. doi:10.1111/j.1755-5922.2010.00146.x

Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
The NAVIGATOR Study Group
N Engl J Med 2010;362:1463-76. Published:22-Apr-2010. Epub:14-Mar-2010. PMID:20228402. doi:10.1056/NEJMoa1001122
[Presentation] [Slides]

Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
The NAVIGATOR Study Group
N Engl J Med 2010;362:1477-90. Published:22-Apr-2010. Epub:14-Mar-2010. PMID:20228403. doi:10.1056/NEJMoa1001121
[Presentation] [Slides]
Erratum in :
N Engl J Med 2010;362:1748, Print:06-May-2010